Premium
Revolution Medicines Inc (RVMD)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-05-26 | Mr. Anthony ManciniChief Global Commercialization Officer | -3,12k | 375,68k | Derivative Exercise and Sale | 33,62 - 154,82 | 54,40k | - |
| 2026-04-27 | Mr. Anthony ManciniChief Global Commercialization Officer | -3,12k | 308,23k | Derivative Exercise and Sale | 33,62 - 134,34 | 54,40k | - |
| 2026-04-15 | Dr. Mark A. GoldsmithCEO, President & Chairman | -120,00k | 17,46M | Derivative Exercise and Sale | 4,09 - 150,09 | 798,46k | - |
| 2026-03-25 | Mr. Anthony ManciniChief Global Commercialization Officer | -37,45k | 2,32M | Derivative Exercise and Sale | 33,62 - 97,21 | 54,40k | - |
| 2026-03-17 | Dr. Wei LinChief Medical Officer | -2,07k | 206,22k | Automatic Disposition | 99,48 | 39,32k | -5,01% |
| 2026-03-17 | Dr. Stephen M. KelseyPresident of Research & Development | -4,30k | 427,96k | Automatic Disposition | 99,48 | 211,15k | -2,00% |
| 2026-03-17 | Dr. Mark A. GoldsmithCEO, President & Chairman | -12,87k | 1,28M | Automatic Disposition | 99,48 | 798,46k | -1,59% |
| 2026-03-17 | Ms. Margaret A. HornCOO | -4,58k | 455,92k | Automatic Disposition | 99,48 | 84,52k | -5,14% |
| 2026-03-17 | Mr. Jack AndersCFO | -2,75k | 273,87k | Automatic Disposition | 99,48 | 68,91k | -3,84% |
| 2026-03-17 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -2,96k | 291,89k | Automatic Disposition | 97,44 - 99,48 | 10,39k | -22,16% |
| 2026-03-17 | Ms. Xiaolin WangExec. VP of Development | -2,01k | 199,96k | Automatic Disposition | 99,48 | 67,36k | -2,90% |
| 2026-03-04 | Ms. Elizabeth McKee AndersonIndependent Director | -15,00k | 0,00 | Other Disposition | - | 47,06k | -24,17% |
| 2026-03-02 | Dr. Mark A. GoldsmithCEO, President & Chairman | -30,00k | 2,91M | Derivative Exercise and Sale | 4,09 - 102,20 | 786,61k | - |
| 2026-03-02 | Dr. Mark A. GoldsmithCEO, President & Chairman | -6,00k | 607,78k | Vente | 98,29 - 102,08 | 786,61k | -0,76% |
| 2026-02-06 | Dr. Mark A. GoldsmithCEO, President & Chairman | 24,01k | 12,97k | Derivative Exercise and Retained Stock | 0,54 | 792,61k | 3,12% |
| 2026-01-21 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -908,00 | 104,96k | Automatic Disposition | 115,60 | 8,21k | -9,96% |
| 2026-01-07 | Ms. Margaret A. HornCOO | -75,00k | 4,66M | Derivative Exercise and Sale | 29,80 - 102,90 | 79,83k | - |
| 2026-01-07 | Mr. Jack AndersCFO | -10,00k | 555,50k | Derivative Exercise and Sale | 42,45 - 98,00 | 65,73k | - |
| 2025-12-16 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -2,69k | 206,48k | Automatic Disposition | 76,82 | 9,12k | -22,77% |
| 2025-12-16 | Dr. Stephen M. KelseyPresident of Research & Development | -5,45k | 418,42k | Automatic Disposition | 76,82 | 205,02k | -2,59% |
| 2025-12-16 | Dr. Mark A. GoldsmithCEO, President & Chairman | -15,39k | 1,18M | Automatic Disposition | 76,82 | 768,60k | -1,96% |
| 2025-12-16 | Ms. Margaret A. HornCOO | -4,85k | 372,33k | Automatic Disposition | 76,82 | 79,83k | -5,72% |
| 2025-12-16 | Mr. Jack AndersCFO | -3,10k | 239,29k | Automatic Disposition | 77,09 | 65,73k | -4,51% |
| 2025-11-25 | Dr. Mark A. GoldsmithCEO, President & Chairman | -60,00k | 4,26M | Derivative Exercise and Sale | 4,09 - 75,08 | 759,29k | - |
| 2025-11-25 | Dr. Mark A. GoldsmithCEO, President & Chairman | -6,00k | 450,00k | Vente | 75,00 | 759,29k | -0,78% |
| 2025-11-25 | Mr. Jack AndersCFO | -5,42k | 308,83k | Derivative Exercise and Sale | 17,00 - 74,00 | 62,72k | - |
| 2025-11-18 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -13,39k | 370,69k | Derivative Exercise and Sale | 42,45 - 70,14 | 6,52k | - |
| 2025-11-18 | Dr. Mark A. GoldsmithCEO, President & Chairman | -20,00k | 1,33M | Derivative Exercise and Sale | 4,09 - 70,38 | 765,29k | - |
| 2025-11-12 | Dr. Mark A. GoldsmithCEO, President & Chairman | -20,00k | 1,22M | Derivative Exercise and Sale | 4,09 - 65,07 | 765,29k | - |
| 2025-11-11 | Mr. Jack AndersCFO | -10,00k | 470,00k | Derivative Exercise and Sale | 17,00 - 64,00 | 62,72k | - |
| 2025-11-07 | Dr. Mark A. GoldsmithCEO, President & Chairman | -30,00k | 1,77M | Derivative Exercise and Sale | 1,12 - 60,31 | 765,29k | - |
| 2025-11-12 | Dr. Mark A. GoldsmithCEO, President & Chairman | -100,00k | 0,00 | Other Disposition | - | 765,29k | -11,56% |
| 2025-10-16 | Dr. Mark A. GoldsmithCEO, President & Chairman | -20,00k | 1,03M | Derivative Exercise and Sale | 1,12 - 55,00 | 765,29k | - |
| 2025-10-17 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -12,00k | 221,16k | Derivative Exercise and Sale | 36,57 - 55,00 | 6,52k | - |
| 2025-10-13 | Dr. Stephen M. KelseyPresident of Research & Development | -25,00k | 1,10M | Derivative Exercise and Sale | 4,73 - 48,54 | 200,05k | - |
| 2025-09-24 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -1,80k | 79,62k | Automatic Disposition | 44,26 | 6,52k | -21,64% |
| 2025-09-16 | Dr. Wei LinChief Medical Officer | -2,16k | 98,98k | Automatic Disposition | 45,82 | 29,49k | -6,82% |
| 2025-09-16 | Dr. Stephen M. KelseyPresident of Research & Development | -5,37k | 245,94k | Automatic Disposition | 45,82 | 200,05k | -2,61% |
| 2025-09-16 | Ms. Margaret A. HornCOO | -4,78k | 218,81k | Automatic Disposition | 45,82 | 75,40k | -5,96% |
| 2025-09-16 | Dr. Mark A. GoldsmithCEO, President & Chairman | -13,41k | 614,56k | Automatic Disposition | 45,82 | 765,29k | -1,72% |
| 2025-09-16 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -1,87k | 85,65k | Automatic Disposition | 45,82 | 8,31k | -18,35% |
| 2025-09-16 | Mr. Jack AndersCFO | -2,32k | 106,31k | Automatic Disposition | 45,82 | 62,72k | -3,57% |
| 2025-09-11 | Dr. Stephen M. KelseyPresident of Research & Development | -125,00k | 4,97M | Derivative Exercise and Sale | 4,73 - 46,93 | 194,99k | - |
| 2025-09-02 | Mr. Jack AndersCFO | -10,00k | 334,32k | Derivative Exercise and Sale | 2,68 - 40,17 | 59,10k | - |
| 2025-06-30 | Dr. Mark A. GoldsmithCEO, President & Chairman | 37,00k | 19,98k | Derivative Exercise and Retained Stock | 0,54 | 753,98k | 5,16% |
| 2025-06-20 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -1,91k | 75,74k | Automatic Disposition | 39,61 | 5,04k | -27,51% |
| 2025-06-16 | Dr. Mark A. GoldsmithCEO, President & Chairman | -13,50k | 537,55k | Automatic Disposition | 39,83 | 716,98k | -1,85% |
| 2025-06-16 | Ms. Margaret A. HornCOO | -3,51k | 139,80k | Automatic Disposition | 39,83 | 70,90k | -4,72% |
| 2025-06-16 | Mr. Jack AndersCFO | -2,17k | 86,43k | Automatic Disposition | 39,83 | 59,10k | -3,54% |
| 2025-06-16 | Mr. Jeffrey CisliniSenior VP, General Counsel & Corporate Secretary | -1,88k | 74,80k | Automatic Disposition | 39,83 | 6,95k | -21,27% |
| 2025-06-16 | Dr. Wei LinChief Medical Officer | -2,17k | 86,55k | Automatic Disposition | 39,83 | 25,70k | -7,80% |
| 2025-06-16 | Dr. Stephen M. KelseyPresident of Research & Development | -4,29k | 170,83k | Automatic Disposition | 39,83 | 194,99k | -2,15% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
